<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02361437</url>
  </required_header>
  <id_info>
    <org_study_id>PVD-01</org_study_id>
    <nct_id>NCT02361437</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers</brief_title>
  <official_title>Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers and Improving Insulin Sensitivity: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Primus Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Primus Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate if Vasculera, a marketed medical food product, will&#xD;
      improve the rate and extent of healing of diabetic ulcers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed primarily to compare the rate and extent of healing of diabetic ulcers&#xD;
      in people treated with or without Vasculera while maintaining a standard of care (SOC)&#xD;
      therapeutic regimen. The study will also examine the effects of Vasculera on anti-diabetic&#xD;
      medication requirements and markers of microvascular disease. Subjects will be stratified by&#xD;
      whether or not they receive hyperbaric oxygen therapy (HBOT) as part of their SOC treatment&#xD;
      regimen. In addition, the study will examine the ability of Vasculera to improve glycemic&#xD;
      control and reduce anti-diabetic medication requirements (oral or injectable insulin) and&#xD;
      will gather preliminary information on the ability of Vasculera to improve microvascular&#xD;
      blood flow and oxygen delivery peripheral tissues including ulcerative lesions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigator's hospital sold and study cancelled&#xD;
  </why_stopped>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of healing of diabetic ulcers measured by ulcer size</measure>
    <time_frame>4 months</time_frame>
    <description>days to complete healinh</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of diabetic control measure by reduction of oral anti-diabetic medication and/or insulin requirements</measure>
    <time_frame>4 months</time_frame>
    <description>anti-diabetic medication doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction on peripheral edema measured by leg circumferance</measure>
    <time_frame>4 months</time_frame>
    <description>leg circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lower extremity skin oxygenation measured by trancutaneous oximetry</measure>
    <time_frame>4 months</time_frame>
    <description>transcutaneous oximetry at toes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Diabetic Ulcers</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vasculera</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>diosmin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vasculera</intervention_name>
    <description>Vasculera 630 mg b.i.d.</description>
    <arm_group_label>Vasculera</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>diosmin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Either gender, between 25-85 years old&#xD;
&#xD;
          2. Diagnosis of type II diabetes&#xD;
&#xD;
          3. Presence of a grade I-III skin ulcer of diabetic origin and at least 1 cm in diameter&#xD;
             for more than 60 days and not improving despite standard conventional care without&#xD;
             HBOT&#xD;
&#xD;
          4. Treatment with oral anti-diabetic agents and/or insulin for at least 1 year. Dose must&#xD;
             be stable for at least 3 months.&#xD;
&#xD;
          5. Not using any other product for control of serum glucose including medical foods,&#xD;
             neutraceuticals or dietary supplements&#xD;
&#xD;
          6. Consistent dietary habits&#xD;
&#xD;
          7. Able to understand and sign informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. age less than 25 years or greater than 85 years&#xD;
&#xD;
          2. Skin ulceration of other than diabetic etiology&#xD;
&#xD;
          3. diagnosis of type I diabetes&#xD;
&#xD;
          4. use of any other serum glucose modifying agent, other than stable prescribed&#xD;
             anti-diabetic medication regimen within 12 weeks of screening visit&#xD;
&#xD;
          5. use of nutritional supplements specifically for anti-oxidative purposes (e.g.,&#xD;
             multivitamins allowed)&#xD;
&#xD;
          6. history of collagen vascular disease&#xD;
&#xD;
          7. taking corticosteroids in any dose, by any route&#xD;
&#xD;
          8. no history of therapy with pentoxyphylline or cilostazol for 2 months prior to the&#xD;
             screening visit and for the duration of the study&#xD;
&#xD;
          9. history of any intestinal disease that might interfere with absorption of study&#xD;
             products&#xD;
&#xD;
         10. any active malignancy or history of malignancy within 3 years of the screening visit,,&#xD;
             except basal cell carcinoma or cervical carcinoma in situ curatively treated&#xD;
&#xD;
         11. screening AST, ALT, alkaline phosphatase, bilirubin &gt;1.3 times the upper limit of&#xD;
             normal for the reference laboratory&#xD;
&#xD;
         12. serum creatinine &gt;3.0&#xD;
&#xD;
         13. diabetes mellitus not on stable therapy for at least 3 months&#xD;
&#xD;
         14. history of chronic pancreatitis&#xD;
&#xD;
         15. uncontrolled hypertension (DBP &gt;100, SPB &gt;160)&#xD;
&#xD;
         16. unstable angina, other uncontrolled cardiac disease including NYHA CHF Class III or IV&#xD;
&#xD;
         17. pregnant or lactating women&#xD;
&#xD;
         18. known history of allergies to citrus, diosmin, or Alka-4 Complex&#xD;
&#xD;
         19. history of substance abuse, or any psychiatric condition that may impair the subject's&#xD;
             ability to comply with the study requirements.&#xD;
&#xD;
         20. Consumption of more than one (1) unit of alcohol daily. For the purposes of this study&#xD;
             a unit of alcohol is defined as 12 oz. of beer, 6 oz. of wine or 1.5 oz. of hard&#xD;
             spirits&#xD;
&#xD;
         21. Concomitant use of chlorzoxazone, diclofenac or metronidazole&#xD;
&#xD;
         22. any medical condition that, in the opinion of the investigator, might put the subject&#xD;
             at undue risk or might interfere with the subject's ability to participate in the&#xD;
             study&#xD;
&#xD;
         23. participation in another clinical trial within 30 days or 7 half-lives of the prior&#xD;
             study product, whichever is longer, of the screening visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert M Levy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Primus Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nix Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>February 4, 2015</study_first_submitted>
  <study_first_submitted_qc>February 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2015</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes type II</keyword>
  <keyword>diabetic ulcers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

